Myris Therapeutics, Inc. — SEC Form D Filing

Myris Therapeutics, Inc. filed an SEC Form D on October 14, 2026, reporting $500K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 14, 2026
Amount reported
$500K
Round stage
Pre-Seed
Industry
Biotechnology
Website
https://www.myristx.com/

What the company does

Securities: Convertible Promissory Notes. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Existing antibody drug conjugates (ADCs) have limitations in payload choice, potentially restricting their effectiveness in targeting various oncogenic pathways.

Solution

Myris Therapeutics is developing next-generation antibody drug conjugates (ADCs) using polymer chemistry to achieve ultra-high Drug-to-Antibody Ratio (DAR), which expands the range of possible therapeutic payloads for targeted cancer therapy.

Why now

Advances in polymer chemistry and a deeper understanding of targeted therapy mechanisms, particularly in oncology, allow for the development of more effective and versatile drug delivery systems like ultra-high DAR ADCs.

Verdict

This cleared because the team articulated a compelling technical advancement in a known high-value therapeutic modality, not because of a fully fleshed out commercialization path. Investors were implicitly betting on the ability to demonstrate a significant *in vivo* efficacy advantage over current ADC platforms, assuming regulatory bodies would eventually favor improved DAR. The limited upside stemmed from the early stage, where the half-million dollar round primarily funded further proof-of-concept, rather than early clinical milestones.

Source: SEC EDGAR Form D filing